Serum albumin: Its relationship to marrow and renal toxicity from platinum-based combination chemotherapy

• Published in: Gynecologic oncology Vol. 37; no. 1; pp. 93 - 95
• Main Authors: Belinson, Jerome L., Jarrell, Maureen A., McClure, Maura, Kulig, Phyllis M., Badger, Gary J.
• Format: Journal Article
• Language: English
• Published: San Diego, CA Elsevier Inc 01.04.1990; Elsevier
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; Biological and medical sciences; Bone Marrow Diseases - blood; Bone Marrow Diseases - chemically induced; Cisplatin - administration & dosage; Creatinine - blood; Cyclophosphamide - administration & dosage; Doxorubicin - administration & dosage; Drug toxicity and drugs side effects treatment; Female; Humans; Kidney Diseases - blood; Kidney Diseases - chemically induced; Leukocyte Count - drug effects; Medical sciences; Middle Aged; Neoplasm Staging; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - mortality; Ovarian Neoplasms - pathology; Pharmacology. Drug treatments; Serum Albumin - metabolism; Survival Rate; Toxicity: blood; Antineoplastic agent; Human; Chemotherapy; Urinary system disease; Treatment; Toxicity; Bone marrow; Exploration; Serum albumin; Kidney
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/0090-8258(90)90315-C

One hundred and three patients treated with CAP chemotherapy were evaluated to determine the relationship between low prechemotherapy serum albumin (<3 g/dl) and low WBC nadir (<2000 cells/mm 3). Additionally, the relationship of serum albumin to renal toxicity (Δ serum creatinine) was examined. Low prechemotherapy serum albumin appears to be a marker for advanced disease, but does not appear to predict marrow or renal toxicity.